Medivir Licenses HDAC Inhibitor Remetinostat to Biossil for Global Cancer Development
核心洞察
Medivir AB has granted exclusive global licensing rights for remetinostat, a topical HDAC (搜索) inhibitor in phase 2 clinical trials, to AI-native drug developer Biossil Inc (搜索).
The compound has demonstrated positive clinical data in basal cell carcinoma (搜索) and cutaneous T-cell lymphoma (搜索), addressing urgent unmet medical needs in cancer treatment.
Under the agreement terms, Medivir could receive up to $60 million in milestone payments plus mid-single digit royalties on future net sales if the drug reaches commercialization.
Medivir AB has entered into an exclusive licensing agreement with Toronto-based Biossil Inc (搜索). for the global development and commercialization of remetinostat, a topical histone deacetylase (HDAC (搜索)) inhibitor currently advancing through phase 2 clinical trials for cancer indications.
Clinical Promise in Oncology Applications
Remetinostat has demonstrated positive clinical data in two distinct cancer types: basal cell carcinoma (搜索) and cutaneous T-cell lymphoma (搜索). The compound's topical formulation and HDAC (搜索) inhibition mechanism represent a differentiated approach to treating these challenging malignancies, which often present significant unmet medical needs for patients.
Financial Terms and Strategic Value
Under the licensing agreement, Biossil receives worldwide development rights while Medivir retains the potential for substantial financial returns. The Swedish pharmaceutical company could receive up to $60 million in milestone payments tied to development and regulatory achievements, along with mid-single digit royalties on future net sales if the drug successfully reaches market.
"Agreements, such as the one announced today with Biossil, continue to be a core component of Medivir's corporate mission and business model," said Jens Lindberg, Chief Executive Officer of Medivir. "Today's announcement further exemplifies our focus and commitment to the development and commercialization of innovative treatments for cancer, and we look forward to Biossil's progress with remetinostat in the clinic and beyond."
AI-Driven Development Approach
Biossil, which describes itself as an AI-native drug developer, specializes in therapies for heterogeneous diseases with urgent unmet medical needs. The company plans to resume remetinostat development using its proprietary computational approach, which identified the compound through rigorous analytical criteria.
"Remetinostat was identified with the same rigorous approach applied to all of Biossil candidates," explained Dr. Alexander Mosa, Co-Founder, Chief Scientific Officer and Chair of Biossil. "It meets our key criteria of promising clinical data, differentiated mechanism of action, and potential to address important unmet need. We are fortunate to have a supportive partner in Medivir, and we will resume development and advance remetinostat in accordance with its clinical potential."
Strategic Partnership Impact
The agreement represents a strategic alignment between Medivir's focus on innovative cancer treatments and Biossil's AI-driven drug development capabilities. For Medivir, the licensing deal allows the company to maintain financial upside while transferring development responsibilities to a specialized partner. For Biossil, the acquisition of remetinostat adds a clinically validated asset with demonstrated efficacy signals to its development pipeline.
The partnership marks a significant step in advancing HDAC (搜索) inhibitor therapy for topical cancer applications, potentially offering new treatment options for patients with basal cell carcinoma (搜索) and cutaneous T-cell lymphoma (搜索) who currently face limited therapeutic alternatives.